Oncolytics Biotech ONCY today announced that it has met
the primary overall statistical endpoint in its U.S. Phase 2 single arm
clinical trial in patients with squamous cell carcinoma of the lung
(SCCLC) using intravenous administration of REOLYSIN in combination
with carboplatin and paclitaxel in patients with metastatic stage IIIB,
or stage IV, or recurrent SCCLC who are chemotherapy naïve for their
metastatic or recurrent cancer (REO 021).
The study is a two-stage design with a primary overall endpoint of
objective tumor response rate. The Company saw a sufficient number of
responses in the first stage of the study to proceed with enrollment in
the second stage. A total of up to 36 patients were to be studied in
the second stage. The primary endpoint was met if nine or more patients
in both stages combined had a partial response (PR) or better, which
yields a true response rate of 35% or more. This endpoint was met after
21 evaluable patients were treated on study, nine of which exhibited
PRs, while a further nine showed stable disease (SD) and three,
progressive disease (PD), for a response rate of 42.8%
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in